Die Darstellungseigenschaften maligner und benigner hepatischer und pulmonaler Läsionen in der 68Ga-PSMA- PET/CT bei Patienten mit Prostatakarzinom
- Alternative title
-
The 68Ga-PSMA-PET/CT imaging properties of malign and benign hepatic and pulmonary lesions in patients with prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Deutsch
- Notes
-
Berlin, Medizinische Fakultät Charité - Universitätsmedizin Berlin, Dissertation, 2024
- Keyword
-
Prostatakrebs
Pulmonale Hypertonie
Patient
Lebermetastase
Metastase
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Medizinische Fakultät Charité - Universitätsmedizin Berlin
- (when)
-
2024
- Creator
- DOI
-
10.17169/refubium-42262
- URN
-
urn:nbn:de:kobv:188-refubium-42538-6
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Damjanovic, Jonathan
- Medizinische Fakultät Charité - Universitätsmedizin Berlin
Time of origin
- 2024
Other Objects (12)
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
68Ga-PSMA and 68Ga-FAPI radioligands in the diagnosis of tumors
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
[68Ga]PSMA-PET/CT-imaging bij de diagnostiek van prostaatkanker
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
68Ga-PSMA als Radiopharmakon für die Prostatakarzinom-Bildgebung : Vergleichende Untersuchung zur Bindung von 68Ga-PSMA durch LNCaP- und PC-3 Zellen in-vitro
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells
Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz® kit and two generators
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
68Ga-PSMA and 68Ga-FAPI radioligands in the diagnosis of tumors
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
[68Ga]PSMA-PET/CT-imaging bij de diagnostiek van prostaatkanker
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
68Ga-PSMA als Radiopharmakon für die Prostatakarzinom-Bildgebung : Vergleichende Untersuchung zur Bindung von 68Ga-PSMA durch LNCaP- und PC-3 Zellen in-vitro
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells
Automated radiolabelling of [68Ga]Ga-PSMA-11 (gallium (68Ga)-gozetotide) using the Locametz® kit and two generators
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
68Ga-PSMA and 68Ga-FAPI radioligands in the diagnosis of tumors
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
[68Ga]PSMA-PET/CT-imaging bij de diagnostiek van prostaatkanker
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
68Ga-PSMA als Radiopharmakon für die Prostatakarzinom-Bildgebung : Vergleichende Untersuchung zur Bindung von 68Ga-PSMA durch LNCaP- und PC-3 Zellen in-vitro
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells